Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Persistence of immunity and impact of a third (booster) dose of an inactivated SARS-CoV-2 vaccine, BBV152; a phase 2, double-blind, randomised controlled trial

Krishna Mohan Vadrevu, Brunda Ganneru, Siddharth Reddy, Harsh Jogdand, Dugyala Raju, Usha Praturi, Gajanan Sapkal, View ORCID ProfilePragya Yadav, Prabhakar Reddy, Savita Verma, Chandramani Singh, Sagar Vivek Redkar, Chandra Sekhar Gillurkar, Jitendra Singh Kushwaha, Satyajit Mohapatra, Amit Bhate, Sanjay Rai, View ORCID ProfileRaches Ella, Priya Abraham, Sai Prasad, Krishna Ella
doi: https://doi.org/10.1101/2022.01.05.22268777
Krishna Mohan Vadrevu
1Bharat Biotech, Hyderabad, India
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brunda Ganneru
1Bharat Biotech, Hyderabad, India
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Siddharth Reddy
1Bharat Biotech, Hyderabad, India
MSc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Harsh Jogdand
1Bharat Biotech, Hyderabad, India
DVM
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dugyala Raju
1Bharat Biotech, Hyderabad, India
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Usha Praturi
1Bharat Biotech, Hyderabad, India
MSc
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gajanan Sapkal
2Indian Council of Medical Research-National Institute of Virology, Pune, India
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pragya Yadav
2Indian Council of Medical Research-National Institute of Virology, Pune, India
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Pragya Yadav
Prabhakar Reddy
3Nizams Institute of Medical Sciences, Hyderabad, India
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Savita Verma
4Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences, Rohtak, India
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chandramani Singh
5All India Institute of Medical Sciences, Patna, India
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sagar Vivek Redkar
6Redkar Hospital, Dargalim, India
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chandra Sekhar Gillurkar
7Gillurkar Hospital, Nagpur, India
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jitendra Singh Kushwaha
8Prakhar Hospital, Kanpur, India
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Satyajit Mohapatra
9SRM Hospital and Research Centre, Kattankulathur, India
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amit Bhate
10Jeevan Rekha Hospital, Belgaum, India
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sanjay Rai
11All India Institute of Medical Sciences, New Delhi, India
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Raches Ella
12Independent Clinical Development Consultant, Cambridge, USA
MBBS, MS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Raches Ella
  • For correspondence: rachesella@gmail.com
Priya Abraham
2Indian Council of Medical Research-National Institute of Virology, Pune, India
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sai Prasad
1Bharat Biotech, Hyderabad, India
MBA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Krishna Ella
1Bharat Biotech, Hyderabad, India
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Background Neutralising antibody responses to SARS-CoV-2 vaccines have been reported to decline within 6 months of vaccination, particularly against Variants of Concern (VOC). We assessed the immunogenicity and safety of a booster dose of BBV152 administered 6 months after the second of a two-dose primary vaccination series.

Methods In an ongoing phase 2 trial (ClinicalTrials.gov: NCT04471519) the protocol was amended after six months to re-consent and randomise 184 previously vaccinated participants to receive a third dose of vaccine or placebo on Day 215. The primary outcome was to measure neutralising antibody titres by plaque-reduction neutralisation test (PRNT50) four weeks after the booster; safety as serious adverse events (SAE) was the key secondary outcome.

Findings Four weeks after a second BBV152 vaccination geometric mean titres (GMTs) of neutralising antibodies were 197·0 PRNT50 (95% CI: 155·6–249·4); this level declined to 23·9 PRNT50 (14·0–40·6) six months later, with a seroconversion rate of 75·4% (95% CI: 68·4–81·6). Four weeks after booster vaccination the GMT increased on Day 243 to 746·6 PRNT50 (514·9–1081) compared with 100·7 PRNT50 (43·6–232·6) in the placebo group. Corresponding seroconversion rates were 98·7% (92·8–99·9) and 79·8% (69·6–87·8). Increased titres in the placebo group were attributed to natural infection as the study was conducted during the second wave of COVID-19 in India. PRNT50 titres against the SARS-CoV-2 variants increased—Alpha (32·6-fold), Beta (161·0-fold), Delta (264·7-fold), and Delta plus (174·2-fold)—after the booster vaccination. We found that vaccine induces both memory B and T cells with a distinct AIM+ specific CD4+T central and effector memory phenotype, including CD8+ TEMRA phenotype. Reactogenicity after vaccine and placebo was minimal and comparable, and no SAEs were reported.

Interpretation Six months after a two-dose BBV152 vaccination series cell mediated immunity and neutralising antibodies to both homologous (D614G) and heterologous strains (Alpha, Beta, Delta and Delta plus) persisted above baseline, although the magnitude of the responses had declined. Neutralising antibodies against homologous and heterologous SARS-CoV-2 variants increased 19- to 97-fold after a third vaccination. Booster BBV152 vaccination is safe and may be necessary to ensure persistent immunity to prevent breakthrough infections.

Funding This work was supported and funded by Bharat Biotech International Limited.

Competing Interest Statement

This work was funded by Bharat Biotech International Limited. Co-author- KE is the Chairman and Managing Director of Bharat Biotech and has stock options in the company. HJ, BG, KMV, SR, DR, UP, SP are employees of Bharat Biotech, with no stock options. RE are independent clinical development consultants. PY, GS, and PA are employees of The National Institute of Virology-The Indian Council of Medical Research. PR, SV, CS, VR, CSG, JSK, SM, AB, and were principal investigators representing the study sites.

Clinical Trial

NCT04471519

Funding Statement

The study sponsor had no role in the collection or analysis of data or writing the report, which was done by the CRO. Unblinded personnel at the CRO and KMV, SRe, BG from Bharat Biotech, and PY from NIV had full access to the data in the study. Authors from Bharat Biotech had final responsibility for the decision to submit for publication.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

1.ECR/303/Inst/AP/2013/RR-19 of Nizam's Institute of Medical Sciences, Hyderabad gave ethical approval for this work 2.ECR/495/Inst/HR/2013/RR-20 of P t B D Sharma, PGIMS/UHS Rohtak gave ethical approval for this work 3.ECR/1387/Inst/BR/2020 of AIIMS, Patna gave ethical approval for this work 4.ECR/902/Inst/GA/2018 of Redkar Hospital and Research center, Goa gave ethical approval for this work 5.ECR/1374/Inst/MH/2020 of Gillurkar Multispeciality Hospitals, Nagpur gave ethical approval for this work 6.ECR/1017/Inst/UP/2017/RR-21 of Prakhar Hospital Pvt Ltd, Kanpur gave ethical approval for this work 7.ECR/431/Inst/TN/2013/RR-19 of SRM Medical College Hospital & Research center, Tamilnadu gave ethical approval for this work 8.ECR/1242/Inst/KA/2019 of Jeevan Rekha Hospital, Belagavi gave ethical approval for this work 9.ECR/538/Inst/DL/2014/RR-20 of AIIMS New Delhi gave ethical approval for this work

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Individual participant (de-identified) data will be made available when the trial is complete upon a direct request to the corresponding author with an appropriate research proposal. After consideration and the approval of such a proposal data will be shared through a secure online platform.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted January 08, 2022.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Persistence of immunity and impact of a third (booster) dose of an inactivated SARS-CoV-2 vaccine, BBV152; a phase 2, double-blind, randomised controlled trial
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Persistence of immunity and impact of a third (booster) dose of an inactivated SARS-CoV-2 vaccine, BBV152; a phase 2, double-blind, randomised controlled trial
Krishna Mohan Vadrevu, Brunda Ganneru, Siddharth Reddy, Harsh Jogdand, Dugyala Raju, Usha Praturi, Gajanan Sapkal, Pragya Yadav, Prabhakar Reddy, Savita Verma, Chandramani Singh, Sagar Vivek Redkar, Chandra Sekhar Gillurkar, Jitendra Singh Kushwaha, Satyajit Mohapatra, Amit Bhate, Sanjay Rai, Raches Ella, Priya Abraham, Sai Prasad, Krishna Ella
medRxiv 2022.01.05.22268777; doi: https://doi.org/10.1101/2022.01.05.22268777
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Persistence of immunity and impact of a third (booster) dose of an inactivated SARS-CoV-2 vaccine, BBV152; a phase 2, double-blind, randomised controlled trial
Krishna Mohan Vadrevu, Brunda Ganneru, Siddharth Reddy, Harsh Jogdand, Dugyala Raju, Usha Praturi, Gajanan Sapkal, Pragya Yadav, Prabhakar Reddy, Savita Verma, Chandramani Singh, Sagar Vivek Redkar, Chandra Sekhar Gillurkar, Jitendra Singh Kushwaha, Satyajit Mohapatra, Amit Bhate, Sanjay Rai, Raches Ella, Priya Abraham, Sai Prasad, Krishna Ella
medRxiv 2022.01.05.22268777; doi: https://doi.org/10.1101/2022.01.05.22268777

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (269)
  • Allergy and Immunology (549)
  • Anesthesia (135)
  • Cardiovascular Medicine (1749)
  • Dentistry and Oral Medicine (238)
  • Dermatology (172)
  • Emergency Medicine (310)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (654)
  • Epidemiology (10785)
  • Forensic Medicine (8)
  • Gastroenterology (584)
  • Genetic and Genomic Medicine (2935)
  • Geriatric Medicine (286)
  • Health Economics (531)
  • Health Informatics (1919)
  • Health Policy (833)
  • Health Systems and Quality Improvement (743)
  • Hematology (290)
  • HIV/AIDS (627)
  • Infectious Diseases (except HIV/AIDS) (12501)
  • Intensive Care and Critical Care Medicine (684)
  • Medical Education (299)
  • Medical Ethics (86)
  • Nephrology (322)
  • Neurology (2785)
  • Nursing (150)
  • Nutrition (431)
  • Obstetrics and Gynecology (556)
  • Occupational and Environmental Health (597)
  • Oncology (1458)
  • Ophthalmology (441)
  • Orthopedics (172)
  • Otolaryngology (255)
  • Pain Medicine (190)
  • Palliative Medicine (56)
  • Pathology (380)
  • Pediatrics (865)
  • Pharmacology and Therapeutics (362)
  • Primary Care Research (334)
  • Psychiatry and Clinical Psychology (2633)
  • Public and Global Health (5342)
  • Radiology and Imaging (1004)
  • Rehabilitation Medicine and Physical Therapy (595)
  • Respiratory Medicine (724)
  • Rheumatology (329)
  • Sexual and Reproductive Health (289)
  • Sports Medicine (278)
  • Surgery (327)
  • Toxicology (47)
  • Transplantation (149)
  • Urology (125)